Anti-CD3/anti-guanylate cyclase 2C/anti-CD28 trispecific T-cell engager (Helixon)

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameAnti-CD3/anti-guanylate cyclase 2C/anti-CD28 trispecific T-cell engager (Helixon)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCD3 T-cell engagersAnti-Heat-stable enterotoxin receptorAnti-CD28
TargetsT cell surface glycoprotein CD3Heat-stable enterotoxin receptorT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHelixon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHelixon Ltd
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A